Charles Aubrey “Mickey” LeMaistre, a former president of MD Anderson Cancer and a pioneer of cancer prevention, died Jan. 27. He was 92.
“Will I still have coverage?”
Patients ask oncologists as Republicans move to gut Affordable Care Act
As Congress lays down the groundwork for dismantling the Affordable Care Act, doctors across America are hearing cancer patients speak of their fear of losing access to care if the law known as “Obamacare” is jettisoned without replacement.
On his last full day as FDA commissioner, Robert Califf announced the formation of the Oncology Center of Excellence and named Richard Pazdur its director.
M2Gen said Merck has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program.
The Scripps Research Institute announced a research collaboration and license agreement with Pfizer Inc. to pioneer new DNA-encoded library technology, including new synthetic chemistry for the creation of next-generation DELs, a potentially transformative technology for early stage drug discovery research.
AbbVie announced four collaborations and investments with leading healthcare innovators to advance early-stage research in key therapeutic areas such as oncology and immunology.
Eli Lilly and Co. announced the expansion of an existing immuno-oncology collaboration with to add a new study of Lilly's Lartruvo (olaratumab) with Keytruda (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma.
Amgen and Immatics Biotechnologies GmbH announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.
Royal Philips and Illumin Inc. announced a strategic collaboration that aims to integrate Illumina's sequencing systems for large-scale analysis of genetic variation and function and Philips' IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the U.S. that want to develop precision medicine programs in oncology.
Genentech said FDA accepted the company's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated or have disease progression at least 12 months after receiving chemotherapy before surgery or after surgery.
